Core Viewpoint - Guizhou Sanli reported a significant decline in revenue and net profit for the third quarter and the first three quarters of the year, indicating financial challenges faced by the company [1] Financial Performance - The revenue for the third quarter was 337 million yuan, representing a year-on-year decrease of 36.10% [1] - The net profit for the third quarter was a loss of 2.274 million yuan [1] - For the first three quarters, the total revenue was 1.038 billion yuan, down 28.24% year-on-year [1] - The net profit for the first three quarters was 80.787 million yuan, reflecting a year-on-year decline of 58.39% [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 回购注销原因：根据贵州三力制药股份有限公司（以下简称"公司"）《2024年限制性股票激励计划 （草案）》的相关规定，授予激励对象欧阳志强先生、谷吉杨先生、王迅先生因离职而不再具备激励资 格，因此由公司对上述3名激励对象已获授但尚未解除限售的140,000股限制性股票予以回购注销；根据 公司《2021年限制性股票激励计划（草案）》的相关规定，公司2024年经营业绩未能达到该计划第三个 解除限售期的解除限售条件，因此由公司对7名激励对象已获授但尚未解除限售的732,000股限制性股票 予以回购注销。 ● 本次注销股份的有关情况 ■ 一、本次限制性股票回购注销的决策与信息披露 1.2025年3月28日，公司召开的第四届董事会第十一次会议和第四届监事会第十次会议，审议通过了 《关于回购注销部分限制性股票的议案》，同意公司以自有资金回购注销2024年限制性股票激励计划中 部分已获授但尚未解除限售的限制性股票合计60,00 ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-056 一、本次限制性股票回购注销的决策与信息披露 1.2025 年 3 月 28 日，公司召开的第四届董事会第十一次会议和第四届监事 会第十次会议，审议通过了《关于回购注销部分限制性股票的议案》，同意公司 以自有资金回购注销 2024 年限制性股票激励计划中部分已获授但尚未解除限售 的限制性股票合计 60,000 股，北京市中伦律师事务所出具了《关于贵州三力制 药股份有限公司限制性股票激励计划之回购注销部分限制性股票事项的法律意 见 书 》 。 具 体 内 容 详 见 公 司 2025 年 3 月 29 日 于 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《贵州三力制药股份有限公司关于回购注销部分限制 性股票的公告》（公告编号：2025-007）。 2.2025年4月21日，公司召开的第四届董事会第十二次会议和第四届监事会 贵州三力制药股份有限公司 股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

北京市中伦律师事务所 关于贵州三力制药股份有限公司 限制性股票激励计划之回购注销部分限制性股票实施情况的 法律意见书 二〇二五年十月 北京市中伦律师事务所 关于贵州三力制药股份有限公司 限制性股票激励计划之回购注销部分限制性股票实施情况的 法律意见书 致：贵州三力制药股份有限公司 根据本所与贵州三力制药股份有限公司（以下简称"贵州三力"或"公司"） 签署的《专项法律服务合同》，本所接受公司的委托担任其本次股权激励计划的 专项法律顾问，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励 管理办法》（以下简称"《管理办法》"）等相关法律、法规和规范性文件以及 《贵州三力制药股份有限公司章程》（以下简称"《公司章程》"）的规定，就 贵州三力2021年限制性股票激励计划第三个解除限售期解除限售条件未成就暨 回购注销部分限制性股票以及2024年限制性股票激励计划部分激励对象已获授 但尚未解除限售的限制性股票予以回购注销（以下统称"本次回购并注销"）的 实施情况出具本法律意见书。 为出具本法律意见书，本所律师对涉及本次激励计划的下述有关方面的事 ...

贵州三力制药股份有限公司 关于控股股东部分股份解除质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 贵州三力制药股份有限公司（以下简称"公司"）控股股东暨实际控制人 张海先生持有公司股份总数 167,668,440 股，占公司总股本的 40.91%。本次解 除质押并再质押后，张海先生累计质押公司股份 80,000,000 股，占其所持有公 司股份总数的 47.71%，占公司总股本的 19.52%。 公司控股股东暨实际控制人张海先生及其一致行动人合计持有公司股份 178,866,387 股，占公司总股本的 43.65%。本次解除质押并再质押后，公司控股 股东及其一致行动人质押股份总数为 80,000,000 股，占控股股东及其一致行动 人合计持有公司股份总数的比例为 44.73%，占公司总股本的比例为 19.52%。 公司将持续关注公司股东所持公司股份的质押、解除质押等情况，严格 遵守相关规定，及时履行信息披露义务，敬请投资者注意投资风险。 公司于近日接到控股股东暨实际控制人张海先生通知，获悉张海 ...

Summary of Guizhou Sanli Conference Call Company Overview - Guizhou Sanli primarily operates in the pharmaceutical industry, focusing on both hospital and over-the-counter (OTC) sales channels. The sales distribution is approximately 60%-70% from hospital channels and 30%-40% from OTC channels [2][4]. Key Points and Arguments - **Sales Channels**: The OTC channel is currently under pressure from retail pharmacies, which may limit short-term revenue growth. However, it holds significant long-term potential as a growth driver [2][3]. - **Acquisitions**: The company has expanded its product matrix through acquisitions of subsidiaries such as Dechangxiang, Haosite, Hanfang Pharmaceutical, and Wudi Pharmaceutical. This strategy enhances market competitiveness and covers various therapeutic areas including gynecology and orthopedic conditions [2][5][10]. - **Core Product Performance**: The core product, Kaihoujian, is crucial for revenue, with significant contributions from both children’s and adult formulations. The company aims to expand its presence in the OTC market while also pushing for inclusion in the essential drug list to boost hospital sales [4][7][8]. - **Financial Performance of Subsidiaries**: - Hanfang Pharmaceutical generates approximately 300-400 million yuan in revenue with a net profit of 40-60 million yuan. - Dechangxiang has around 100 million yuan in revenue and a net profit of about 15 million yuan. - Wudi Pharmaceutical focuses on orthopedic products, with revenue between 20-30 million yuan and a net profit of 3-5 million yuan [2][9][10]. Future Growth Drivers - The future growth of Kaihoujian is expected to come from: - Expanding the children’s formulation in the OTC market. - Enhancing the adult formulation's coverage across all sales channels. - Successful inclusion in the essential drug list, which would significantly increase hospital market penetration [7][8]. Key Factors for Future Development - The ability of Kaihoujian to be included in the essential drug list is critical for increasing market share. - The development of the OTC channel, including coverage in chain pharmacies and grassroots medical institutions, is essential. - Effective integration of newly acquired subsidiaries to improve overall productivity and profitability is vital for long-term success [8][11]. Challenges - Guizhou Sanli faces significant challenges from pressure in the OTC retail sector, which is expected to limit short-term revenue and profit growth. The company must closely monitor the impact of essential drug list adjustments and the integration of acquired subsidiaries to achieve expected returns [3][11].

Market Overview - The Shanghai Composite Index is at 3916.86 points, above the annual line, with a change of 0.12% [1] - The total trading volume of A-shares is 909.4 billion yuan [1] Stocks Breaking Annual Line - A total of 20 A-shares have surpassed the annual line today, with notable stocks including: - Shenglong Co., Ltd. (603178) with a deviation rate of 9.96% - Lege Co., Ltd. (300729) with a deviation rate of 2.14% - Jinguang Co., Ltd. (300510) with a deviation rate of 1.75% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates after breaking the annual line: - Shenglong Co., Ltd. (603178): Today's change of 10.00%, turnover rate of 4.72%, latest price at 21.45 yuan [1] - Lege Co., Ltd. (300729): Today's change of 4.01%, turnover rate of 4.10%, latest price at 15.58 yuan [1] - Jinguang Co., Ltd. (300510): Today's change of 2.00%, turnover rate of 5.62%, latest price at 4.60 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Changjiang Electric Power (600900): Today's change of 0.36%, latest price at 28.03 yuan, deviation rate of 0.01% [2] - Beiqi Blue Valley (600733): Today's change of 3.05%, latest price at 8.11 yuan, deviation rate of 0.03% [2] - Hongcheng Environment (600461): Today's change of 0.22%, latest price at 9.10 yuan, deviation rate of 0.05% [2]

Group 1 - Guizhou Sanli announced that as of October 2, 2025, Yueshin Pharmaceutical completed its share reduction plan, selling approximately 810,000 shares, which accounts for 0.1976% of the company's total share capital [1] - The company's revenue composition for the year 2024 indicates that the pharmaceutical manufacturing sector contributes 99.97% to its total revenue, while other businesses account for only 0.03% [1] Group 2 - As of the latest report, Guizhou Sanli has a market capitalization of 5.1 billion yuan [2]

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次股份减持计划实施前，贵州三力制药股份有限公司（以下简称"公 司"）持股 5%以上股东海南悦欣医药投资合伙企业（普通合伙）（以下简称 "悦欣医药"）持有公司无限售条件流通股 21,000,000 股，占公司总股本 的 5.1244%，股份来源为协议转让。 减持计划的实施结果情况 公司于 2025 年 6 月 12 日披露了《贵州三力制药股份有限公司持股 5% 以上股东及董事、高管减持股份计划公告》（公告编号：2025-033）。按照 悦欣医药的减持计划，悦欣医药拟自 2025 年 7 月 3 日至 2025 年 10 月 2 日，通过集中竞价交易方式减持其所持有的公司股份合计不超过 2,049,011 股（不超过公司总股本的 0.5000%)。 证券代码：603439 证券简称：贵州三力 公告编号：2025-054 贵州三力制药股份有限公司 股东减持股份计划期限届满暨减持结果公告 二、减持计划的实施结果 （一）股东因以下事项披露减持 ...

Group 1 - The major shareholder, Hainan Yuexin Pharmaceutical Investment Partnership (General Partnership), has completed its share reduction plan, selling 809,900 shares of Guizhou Sanli, which accounts for 0.1976% of the total share capital [1] - After the reduction, the major shareholder holds 20,190,100 shares, representing 4.9268% of the total shares [1] - The initial plan was to reduce holdings by up to 2,049,000 shares, which would have represented 0.5000% of the total share capital [1]